vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Urban Edge Properties (UE). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $132.6M, roughly 1.3× Urban Edge Properties). Urban Edge Properties runs the higher net margin — 17.1% vs 1.6%, a 15.4% gap on every dollar of revenue. On growth, Urban Edge Properties posted the faster year-over-year revenue change (12.2% vs 5.0%). Over the past eight quarters, Urban Edge Properties's revenue compounded faster (11.6% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Urban Edge Properties is a publicly traded real estate investment trust (REIT) that owns, operates, and develops high-quality retail and mixed-use properties, primarily located in densely populated urban and suburban markets across the United States. Its portfolio covers grocery-anchored shopping centers, lifestyle outlets, and community-focused commercial assets.
PCRX vs UE — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $132.6M |
| Net Profit | $2.9M | $22.6M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | — |
| Net Margin | 1.6% | 17.1% |
| Revenue YoY | 5.0% | 12.2% |
| Net Profit YoY | — | -6.7% |
| EPS (diluted) | $0.07 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $132.6M | ||
| Q4 25 | $196.9M | $119.6M | ||
| Q3 25 | $179.5M | $120.1M | ||
| Q2 25 | $181.1M | $114.1M | ||
| Q1 25 | $168.9M | $118.2M | ||
| Q4 24 | $187.3M | $116.4M | ||
| Q3 24 | $168.6M | $112.4M | ||
| Q2 24 | $178.0M | $106.5M |
| Q1 26 | $2.9M | $22.6M | ||
| Q4 25 | — | $12.4M | ||
| Q3 25 | $5.4M | $14.9M | ||
| Q2 25 | $-4.8M | $58.0M | ||
| Q1 25 | $4.8M | $8.2M | ||
| Q4 24 | — | $30.1M | ||
| Q3 24 | $-143.5M | $9.1M | ||
| Q2 24 | $18.9M | $30.8M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 11.3% | ||
| Q3 25 | 3.5% | 13.4% | ||
| Q2 25 | 4.7% | 53.9% | ||
| Q1 25 | 1.2% | 7.6% | ||
| Q4 24 | 13.2% | 27.6% | ||
| Q3 24 | -82.8% | 8.9% | ||
| Q2 24 | 15.9% | 30.6% |
| Q1 26 | 1.6% | 17.1% | ||
| Q4 25 | — | 10.4% | ||
| Q3 25 | 3.0% | 12.4% | ||
| Q2 25 | -2.7% | 50.8% | ||
| Q1 25 | 2.8% | 6.9% | ||
| Q4 24 | — | 25.9% | ||
| Q3 24 | -85.1% | 8.1% | ||
| Q2 24 | 10.6% | 28.9% |
| Q1 26 | $0.07 | $0.18 | ||
| Q4 25 | $0.05 | $0.09 | ||
| Q3 25 | $0.12 | $0.12 | ||
| Q2 25 | $-0.11 | $0.46 | ||
| Q1 25 | $0.10 | $0.07 | ||
| Q4 24 | $0.38 | $0.25 | ||
| Q3 24 | $-3.11 | $0.07 | ||
| Q2 24 | $0.39 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $50.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $1.4B |
| Total Assets | $1.2B | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $50.0M | ||
| Q4 25 | $238.4M | $48.9M | ||
| Q3 25 | $246.3M | $77.8M | ||
| Q2 25 | $445.9M | $53.0M | ||
| Q1 25 | $493.6M | $48.0M | ||
| Q4 24 | $484.6M | $41.4M | ||
| Q3 24 | $453.8M | $67.9M | ||
| Q2 24 | $404.2M | $78.6M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | $1.4B | ||
| Q4 25 | $693.1M | $1.4B | ||
| Q3 25 | $727.2M | $1.4B | ||
| Q2 25 | $757.8M | $1.4B | ||
| Q1 25 | $798.5M | $1.4B | ||
| Q4 24 | $778.3M | $1.4B | ||
| Q3 24 | $749.6M | $1.3B | ||
| Q2 24 | $879.3M | $1.3B |
| Q1 26 | $1.2B | $3.4B | ||
| Q4 25 | $1.3B | $3.3B | ||
| Q3 25 | $1.3B | $3.3B | ||
| Q2 25 | $1.5B | $3.3B | ||
| Q1 25 | $1.6B | $3.3B | ||
| Q4 24 | $1.6B | $3.3B | ||
| Q3 24 | $1.5B | $3.2B | ||
| Q2 24 | $1.6B | $3.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $39.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | — | 1.73× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $39.1M | ||
| Q4 25 | $43.7M | $182.7M | ||
| Q3 25 | $60.8M | $55.7M | ||
| Q2 25 | $12.0M | $43.5M | ||
| Q1 25 | $35.5M | $32.6M | ||
| Q4 24 | $33.1M | $153.2M | ||
| Q3 24 | $53.9M | $36.6M | ||
| Q2 24 | $53.2M | $41.2M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $81.8M | ||
| Q3 25 | $57.0M | $26.1M | ||
| Q2 25 | $9.3M | $19.6M | ||
| Q1 25 | $26.9M | $11.9M | ||
| Q4 24 | $31.0M | $42.5M | ||
| Q3 24 | $49.8M | $12.2M | ||
| Q2 24 | $51.6M | $19.9M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 68.4% | ||
| Q3 25 | 31.7% | 21.7% | ||
| Q2 25 | 5.1% | 17.2% | ||
| Q1 25 | 15.9% | 10.0% | ||
| Q4 24 | 16.6% | 36.6% | ||
| Q3 24 | 29.6% | 10.8% | ||
| Q2 24 | 29.0% | 18.6% |
| Q1 26 | — | 1.5% | ||
| Q4 25 | 0.1% | 84.4% | ||
| Q3 25 | 2.2% | 24.6% | ||
| Q2 25 | 1.5% | 20.9% | ||
| Q1 25 | 5.1% | 17.5% | ||
| Q4 24 | 1.1% | 95.1% | ||
| Q3 24 | 2.4% | 21.7% | ||
| Q2 24 | 0.9% | 20.1% |
| Q1 26 | — | 1.73× | ||
| Q4 25 | — | 14.71× | ||
| Q3 25 | 11.20× | 3.73× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | 7.37× | 3.97× | ||
| Q4 24 | — | 5.09× | ||
| Q3 24 | — | 4.03× | ||
| Q2 24 | 2.82× | 1.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
UE
| Rental revenue | $124.2M | 94% |
| Other | $8.4M | 6% |
